Helping good genes win in brain cancer cells

December 20, 2013

Researchers at the Federal University of Rio Grande do Sul (UFRGS) have shown that manipulating an epigenetic mechanism, which regulates gene expression, may promote cell death and favor maturation towards less malignant-prone phenotypes in pediatric brain cancer cell lines.

Cancer show alterations in gene expression related to modifications in the state of their chromatin, the "package" containing the genes in the cell nucleus. A group of enzymes called (HDACs) helps to organize DNA within the by keeping chromatin in a more condensed state, thus inhibiting gene expression. The HDAC system is one component in the set of that regulate gene readout. There is growing interest in investigating compounds that inhibit HDACs, thereby allowing chromatin relaxation and increased , as candidate anticancer drugs.

Medulloblastoma is the most common type of childhood . Although cure rates have improved, about 30% of patients with medulloblastoma tumors still have a low chance of being cured and survivors often experience long-term neurocognitive and neuroendocrine impairments.

In a study published in the December 2013 issue of the journal Molecular Neurobiology, Carolina Nör and colleagues – namely, study leader Rafael Roesler, ICI-RS researchers Caroline Brunetto de Farias, Ana Lucia Abujamra, and Algemir Lunardi Brunetto, and UFRGS and HCPA researchers Gilberto Schwartsmann, Felipe A. Sassi, and Guido Lenz - showed that sodium butyrate, a drug that acts on epigenetic regulation by inhibiting HDACs, reduces the survival of cultured medulloblastoma cells as well as formation of neurospheres in the cell cultures, which may indicate inhibition of stem cell proliferation. In addition, cells treated with sodium butyrate showed enhanced mRNA expression of a marker of differentiation towards a mature neuronal phenotype. Finally, sodium butyrate enhanced the anticancer effect of the chemotherapeutic drug etoposide. These findings support and extend previous evidence indicating that HDAC inhibitors can reduce brain tumor growth by allowing genes involved in the promotion of cell death and maturation to be expressed.

"The use of HDAC inhibitors is currently the most important pharmacological approach to manipulate the epigenome. We are using cultured human brain tumor cell lines to identify novel effects of HDAC inhibitors. Although these findings need to be confirmed by in vivo experiments as well as by studies using cancer cells obtained directly from patients, our results support the view that these agents can allow the expression of genes related to , or those involved in differentiation of tumor cells into mature brain cell types, hence having anticancer effects", says Roesler.

In addition to public research funding organizations, including the National Council for Scientific and Technological Development (CNPq) and the National Institute for Translational Medicine (INCT-TM), major support for the study was provided by the Rafael Koff Acordi Project, a research fund created by the Koff Acordi family in partnership with ICI-RS. "It is still uncommon to see basic cancer research being supported by private donations in Brazil, and we are working to promote this type of initiative", says Remi Acordi. "Our goal is to increasingly engage in basic research informed by clinical needs", says Algemir Brunetto, President of ICI-RS, a non-profit private organization focused on pediatric cancer treatment and research.

Explore further: Targets of anticancer drugs have broader functions than what their name suggests

More information: Carolina Nör, Felipe A. Sassi, Caroline B. de Farias, Gilberto Schwartsmann, Ana Lucia Abujamra, Guido Lenz, Algemir L. Brunetto, Rafael Roesler. The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells. Molecular Neurobiology 2013, 48: 533-543.

Related Stories

Targets of anticancer drugs have broader functions than what their name suggests

November 21, 2013
Drugs that inhibit the activity of enzymes called histone deacetylases (HDACs) are being widely developed for treating cancer and other diseases, with two already on the market. Researchers at the Perelman School of Medicine, ...

Surprising role of gene regulator protein in development of skin tumors

November 18, 2013
Findings by scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna reveal a surprising role for histone deacetylase 1 (HDAC1) – a member of a family of chromatin ...

BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy

October 30, 2013
A review article by researchers at Boston University School of Medicine (BUSM) suggests that epigenetics may be a useful target to stop the growth, spread and relapse of cancer. The findings are published online in Volume ...

New approach to treating human brain cancer could lead to improved outcomes

September 25, 2013
A new experimental approach to treating a type of brain cancer called medulloblastoma has been developed by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham). The method targets cancer stem cells—the ...

Researchers identify fundamental differences between human cancers and genetically engineered mouse models of cancer

December 5, 2013
Researchers from the Fred Hutchinson Cancer Research Center in Seattle, WA have taken a closer look at existing mouse models of cancer, specifically comparing them to human cancer samples. These genetically engineered mouse ...

Blocking DNA: HDAC inhibitor targets triple negative breast cancer

May 21, 2012
The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research. Researchers ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.